Press release
Cardiometabolic Diseases Market Analysis 2024-2033 : Forecast Market Size, Top Segments And Largest Region | Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co Inc.
Cardiometabolic Diseases Global Market Report
The Business Research Company presents an extensive market research report on the Cardiometabolic Diseases Global Market Report 2024, furnishing businesses with a competitive edge through a detailed examination of the market structure, encompassing estimates for various segments and sub-segments.
Furthermore, the report highlights on emerging trends, significant drivers, challenges, and opportunities, providing all necessary data for thriving in the industry. This report market research offers a comprehensive perspective, including an in-depth analysis of the present and future scenarios within the industry.
Market Sizing:
The cardiometabolic diseases market size has grown steadily in recent years. It will grow from $106.3 billion in 2023 to $110.9 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to sedentary lifestyles, urbanization and lifestyle shifts, industrialization and processed foods, genetic predispositions, environmental factors.
The cardiometabolic diseases market size is expected to see steady growth in the next few years. It will grow to $128.98 billion in 2028 at a compound annual growth rate (CAGR) of 3.8%. The growth in the forecast period can be attributed to obesity epidemic, aging population continues, healthcare infrastructure development, genomic and precision medicine, chronic stress and mental health. Major trends in the forecast period include health education and awareness, corporate wellness programs, community health programs, prevention-centric healthcare, integrated care approaches.
Request for free sample report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=11929&type=smp
Key Market Players:
Major companies operating in the cardiometabolic diseases market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Kowa Company Ltd., Thermo Fisher Scientific, Abbott Laboratories, Takeda Pharmaceutical Company, Eli Lilly and Company, Novo Nordisk A/S, Siemens Healthineers, Boehringer Ingelheim International GmbH, Becton, Dickinson and Company, Stryker Corporation, AstraZeneca Plc, Viatris Inc., Biocrates Life Sciences AG, Boston Scientific, Astellas Pharma Inc., Terumo Corporation, Agilent Technologies, Edwards Lifesciences, Bruker Corporation, Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Cardax Inc.
Market Drivers:
A high rate of obesity is expected to propel the growth of the cardiometabolic disease market going forward. Obesity is a complex condition characterized by the excessive accumulation of body fat, leading to higher body weight. Obesity directly influences the occurrence of cardiovascular risk factors such as dyslipidemia, type 2 diabetes, hypertension, and sleep problems. For instance, in March 2022, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, over 1 billion individuals are affected by obesity globally, which included 340 million teenagers, 650 million adults, and 39 million kids each year. By 2025, the WHO predicts that 167 million adults and children are going to lose some of their health due to being overweight or obese. Therefore, the high rate of obesity is driving the growth of the cardiometabolic diseases market.
Learn More About The Market Report -
https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report
The cardiometabolic diseases market covered in this report is segmented -
1) By Type: Chronic/Congestive Heart Failure, Hypertension, Type 2 Diabetes, Obesity
2) By Treatment: ACE inhibitors, Diuretics, Glucophage, Liposuction, Other Treatments
3) By Dosage: Tablet, Injection
4) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration
5) By End-Users: Clinic, Hospital, Other End-Users
The report answers the following questions:
What are the primary factors propelling the market during the projected period?
In which region is the most substantial growth expected?
Which trend will take center stage in the upcoming period?
Want To Know More About The Business Research Company?
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.
Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cardiometabolic Diseases Market Analysis 2024-2033 : Forecast Market Size, Top Segments And Largest Region | Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co Inc. here
News-ID: 3380875 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Cardiometabolic
Cardiometabolic Disease Market to Reach $60.81B by 2035
Cardiometabolic Disease Market Poised for Steady Growth Amid Rising Global Health Concerns
Tackling the Global Cardiometabolic Health Crisis
Cardiometabolic diseases-including obesity, type 2 diabetes, hypertension, and chronic heart failure-represent a major global health challenge, contributing to morbidity, mortality, and escalating healthcare costs. These interlinked conditions share common risk factors such as sedentary lifestyle, unhealthy diets, and aging populations, creating a pressing need for effective preventive and therapeutic interventions.
The global cardiometabolic disease market…
Rising Obesity Rates Fuel Growth In Cardiometabolic Disease Market: Powering Inn …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Cardiometabolic Diseases Market Through 2025?
The valuation of the cardiometabolic diseases sector has experienced consistent expansion over the last several years, projected to climb from $111.64 billion in 2024 up to $115.27 billion the following year, reflecting a 3.3% compound annual growth…
Charting a New Era in Cardiometabolic Care: The Global Cardiometabolic Drug Mark …
In an era defined by rising rates of obesity, diabetes, and cardiovascular disease, the global cardiometabolic drug market has emerged as a cornerstone of modern healthcare. Spanning therapies for type 2 diabetes, dyslipidemia, hypertension, and related metabolic disorders, this market is not only addressing some of the world's most pressing health challenges but is also redefining standards of patient care through precision targeted medicines, innovative delivery systems, and breakthrough combination…
Rising Obesity Rates Fuel Growth In Cardiometabolic Disease Market: Key Factor D …
The Cardiometabolic Diseases Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Cardiometabolic Diseases Market Size During the Forecast Period?
The Cardiometabolic Diseases Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This…
Cardiometabolic Diseases Market Embraces Advanced Solutions Trend: A Crucial Inf …
What industry-specific factors are fueling the growth of the cardiometabolic diseases market?
The cardiometabolic disease market is projected to grow due to the anticipated rise in obesity rates. Being a multifaceted disorder, obesity is identified by an overly excessive accumulation of fat in the body, resulting in increased body weight. This directly impacts the occurrence of cardiovascular risk determinants such as dyslipidemia, type 2 diabetes, hypertension, and sleep disorders. For example,…
Cardiometabolic Diseases Market Analysis & Opportunities 2024-2033
"The Business Research Company recently released a comprehensive report on the Global Cardiometabolic Diseases Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
